Considering that RIP2 can induce TMZ resistance in glioma cells, we pretreated the resistant cells (T98G/TR and U87MG/TR) and RIP2‐overexpressing cells (T98G and U87MG) with NF‐κB chemical inhibitors (SC75741, SN50, and JSH‐23) and an MGMT chemical inhibitor (lomeguatrib), respectively. Here, NFKB1 is linked to glioma.